checkAd
    Startseite > Aktien > TG Therapeutics > Nachrichten
    TG Therapeutics Aktie
    16,850
     
    USD
    +0,84 %
    +0,140 USD
    Letzter Kurs 02:00:00 Nasdaq
    16,850
     
    USD
    300 STK
    Geldkurs 28.05.24
    16,870
     
    USD
    9.800 STK
    Briefkurs 28.05.24
    ISIN: US88322Q1085 · WKN: A1JXW7 · SYM: TGTX · USA

    Neueste Nachrichten

    TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
    28.05.24 · globenewswire · TG Therapeutics
    TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
    01.05.24 · globenewswire · TG Therapeutics
    TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
    30.04.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Additional Data Presentations for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
    18.04.24 · globenewswire · TG Therapeutics
    TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis
    18.04.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
    15.04.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
    08.03.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
    01.03.24 · globenewswire · TG Therapeutics
    TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
    28.02.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI (ublituximab-xiiy)
    27.02.24 · globenewswire · TG Therapeutics
    TG Therapeutics Announces European Launch of BRIUMVI (ublituximab-xiiy)
    26.02.24 · globenewswire · TG Therapeutics
    TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2023 Financial Results and Business Update
    23.02.24 · globenewswire · TG Therapeutics